Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients-Reference-Cited by-同舟云学术

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Published:2001-03 Issue:3 Volume:29 Page:503-510
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:Critical Care Medicine

Author:

Abraham Edward,Laterre Pierre-François,Garbino Jorge,Pingleton Susan,Butler Thomas,Dugernier Thierry,Margolis Benjamin,Kudsk Kenneth,Zimmerli Werner,Anderson Paula,Reynaert Marc,Lew Daniel,Lesslauer Werner,Cooper Sharon Passe; Philip,Burdeska Alex,Modi Marlene,Leighton Anton,Salgo Miklos,Van der Auwera Philippe

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference14 articles.

1. The pathogenesis of septic shock

2. The Pathophysiology of Tumor Necrosis Factors

3. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality

4. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunomodulatory mechanism of acupuncture treatment for ischemic stroke: research progress, prospects, and future direction;Frontiers in Immunology;2024-05-02

2. Design, Synthesis, and Biological Evaluation of a Novel NIK Inhibitor with Anti-Inflammatory and Hepatoprotective Effects for Sepsis Treatment;Journal of Medicinal Chemistry;2024-04-02

3. Protective Effect of Ketotifen on Cardiac Dysfunction in Septic Rats Induced by LPS through Regulation of the PD-1/PD-L1 Pathway;J BIOL REG HOMEOS AG;2024

4. Anti-Tumour Necrosis Factor and New Paradigms for Therapies Using Antibodies;Molecular Biology of B Cells;2024

5. Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury;Cytokine & Growth Factor Reviews;2023-06